Teva Pharmaceuticals to make 1,000 of its employees redundant following its acquisition of US-based Cephalon last month.

The cuts represent approximately 27% of Cephalon’s entire workforce.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The company has expected to gather at least $500m in synergies as a result of the acquisition.

The layoffs will not affect Teva’s operations in its home nation Israel, but instead in the US and Europe.

Teva CEO Shlomo Yanai is currently in the US overseeing the merger of Cephalon’s interests.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now